From Immunogen CEO Discussion on Q1 2014 Earnings Results Seeking Alpha approx page 6:
AMG 172 targets CD70 that would be for clear cell renal cell carcinoma. Studies for both of these compounds began in the first half of 2012. That lends itself to the possibility of data disclosures next year, but we'll have to see on that. Recall Amgen took two additional licenses over the past year. They have no further rights to take licenses to our technology.